Evolving health effects of Pneumocystis: One hundred years of progress in diagnosis and treatment

JAMA

Volumn 301, Issue 24, 2009, Pages 2578-2585

  Kovacs, Joseph A ^a   Masur, Henry ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; FLUDARABINE; PENTAMIDINE; PREDNISOLONE; RITUXIMAB; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; GLUCOCORTICOID; PREDNISONE;

ADRENAL GLAND; ADULT; ARTICLE; ASPERGILLUS; AUTOPSY; BONE MARROW; BRONCHOSCOPY; CANDIDA; CASE REPORT; CAUSE OF DEATH; CHRONIC LYMPHATIC LEUKEMIA; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DISEASE COURSE; DRUG HYPERSENSITIVITY; DYSPNEA; FEVER; FLUORESCENCE; FUNGUS IDENTIFICATION; GENE SEQUENCE; HEMOLYTIC ANEMIA; HERPES SIMPLEX; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCOMPROMISED PATIENT; INFECTION PREVENTION; INTUBATION; LEUKEMIA CELL; LUNG; LUNG LAVAGE; LUNG PARENCHYMA; LYMPH NODE; MALE; MULTIPLE CYCLE TREATMENT; PHYSICAL EXAMINATION; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY FAILURE; THORAX RADIOGRAPHY; CLASSIFICATION; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; IMMUNE DEFICIENCY; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIDDLE AGED; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS;

ANTI-INFECTIVE AGENTS; ANTIFUNGAL AGENTS; GLUCOCORTICOIDS; HUMANS; IMMUNOCOMPROMISED HOST; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PENTAMIDINE; PNEUMOCYSTIS; PNEUMONIA, PNEUMOCYSTIS; PREDNISONE; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 67649199980     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2009.880     Document Type: Article

References (67)

1. Chagas C. Nova tripanozomiaze humana. Mem Inst Oswaldo Cruz. 1909;1:159-218.
2. Chagas C. Nova entidade mórbida do homem: resumo geral de estudos etiológicos e clínicos. Mem Inst Oswaldo Cruz. 1911;3:219-275.
3. Delanoe P, Delanoe M. Sur les rapports des kystes de Carini du poumon des rats avec le Trypanosoma lewisi. C R Acad Sci Gen. 1912;155:658-660.
4. Van der Meer G, Brug SL. Infection a Pneumocystis chez l'homme et chez les animaux. Ann Soc Belg Med Trop. 1942;22:301-307.
5. Vanek J, Jirovek O. Parasitare Plasmazellenpneumonie " Interstitielle" Plasmazellenpneumonie der Fruhgeborenen, verursacht durch Pneumocystis carinii. Zentralbl Bakteriol Orig A. 1952;158:120-127.
6. Hughes WT, Price RA, Kim HK, Coburn TP, Grigsby D, Feldman S. Pneumocystis carinii pneumonitis in children with malignancies. J Pediatr. 1973;82(3):404-415.
7. Walzer PD, Perl DP, Krogstad DJ, Rawson PG, Schultz MG. Pneumocystis carinii pneumonia in the United States: epidemiologic, diagnostic, and clinical features. Ann Intern Med. 1974;80(1):83-93.
8. Gottlieb MS, Schroff R, Schanker HM, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med. 1981;305(24):1425-1431.
9. Masur H, Michelis MA, Greene JB, et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med. 1981;305(24):1431-1438.
10. Vargas SL, Ponce CA, Hughes WT, et al. Association of primary Pneumocystis carinii infection and sudden infant death syndrome. Clin Infect Dis. 1999;29(6):1489-1493.
11. Vargas SL, Ponce CA, Galvez P, et al. Pneumocystis is not a direct cause of sudden infant death syndrome. Pediatr Infect Dis J. 2007;26(1):81-83.
12. Morris A, Sciurba FC, Lebedeva IP, et al. Association of chronic obstructive pulmonary disease severity and Pneumocystis colonization.AmJ Respir Crit Care Med. 2004;170(4):408-413.
13. Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;30(suppl 1):S5-S14.
14. Edman JC, Kovacs JA, Masur H, Santi DV, Elwood HJ, Sogin ML. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature. 1988;334(6182):519-522.
15. Kovacs JA, Halpern JL, Swan JC, Moss J, Parrillo JE, Masur H. Identification of antigens and antibodies specific for Pneumocystis carinii. J Immunol. 1988;140(6):2023-2031.
16. Stringer JR, Beard CB, Miller RF, Wakefield AE. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis. 2002;8(9):891-896.
17. Gigliotti F. Pneumocystis carinii: has the name really been changed? Clin Infect Dis. 2005;41(12):1752-1755.
18. Worodria W, Okot-Nwang M, Yoo SD, Aisu T. Causes of lower respiratory infection in HIV-infected Ugandan adults who are sputum AFB smear-negative. Int J Tuberc Lung Dis. 2003;7(2):117-123.
19. Hughes WT. Natural mode of acquisition for de novo infection with Pneumocystis carinii. J Infect Dis. 1982;145(6):842-848.
20. Meuwissen JH, Tauber I, Leeuwenberg AD, Beckers PJ, Sieben M. Parasitologic and serologic observations of infection with Pneumocystis in humans. J Infect Dis. 1977;136(1):43-49.
21. Beard CB, Fox MR, Lawrence GG, et al. Genetic differences in Pneumocystis isolates recovered from immunocompetent infants and from adults with AIDS: epidemiological implications. J Infect Dis. 2005;192(10):1815-1818.
22. Simonds RJ, Oxtoby MJ, Caldwell MB, Gwinn ML, Rogers MF. Pneumocystis carinii pneumonia among US children with perinatally acquired HIV infection. JAMA. 1993;270(4):470-473.
23. Vestereng VH, Bishop LR, Hernandez B, Kutty G, Larsen HH, Kovacs JA. Quantitative real-time polymerase chain-reaction assay allows characterization of Pneumocystis infection in immunocompetent mice. J Infect Dis. 2004;189(8):1540-1544.
24. Huang L, Beard CB, Creasman J, et al. Sulfa or sulfone prophylaxis and geographic region predict mutations in the Pneumocystis carinii dihydropteroate synthase gene. J Infect Dis. 2000;182(4):1192-1198.
25. Kazanjian P, Armstrong W, Hossler PA, et al. Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients. J Infect Dis. 2000;182(2):551-557.
26. Ma L, Borio L, Masur H, Kovacs JA. Pneumocystis carinii dihydropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use. J Infect Dis. 1999;180(6):1969-1978.
27. Schmoldt S, Schuhegger R, Wendler T, et al. Molecular evidence of nosocomial Pneumocystis jirovecii transmission among 16 patients after kidney transplantation. J Clin Microbiol. 2008;46(3):966-971.
28. Ma L, Kutty G, Jia Q, et al. Analysis of variation in tandem repeats in the intron of the major surface glycoprotein expression site of the human form of Pneumocystis carinii. J Infect Dis. 2002;186(11):1647-1654.
29. Nahimana A, Blanc DS, Francioli P, Bille J, Hauser PM. Typing of Pneumocystis carinii f. sp. hominis by PCR-SSCP to indicate a high frequency of co-infections. J Med Microbiol. 2000;49(8):753-758.
30. Helweg-Larsen J, Lee CH, Jin S, et al. Clinical correlation of variations in the internal transcribed spacer regions of rRNA genes in Pneumocystis carinii f. sp. hominis. AIDS. 2001;15(4):451-459.
31. Phair J, Munoz A, Detels R, Kaslow R, Rinaldo C, Saah A; Multicenter AIDS Cohort Study Group. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. N Engl J Med. 1990;322(3):161-165.
32. Guidelines for prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: June 20, 2008. http://aidsinfo.nih.gov/ contentfiles/Pediatric-OI.pdf. Accessed April 23, 2009.
33. Mansharamani NG, Balachandran D, Vernovsky I, Garland R, Koziel H. Peripheral blood CD4 + T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection. Chest. 2000;118(3):712-720.
34. Byrd JC, Hargis JB, Kester KE, Hospenthal DR, Knutson SW, Diehl LF. Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis. Am J Hematol. 1995;49(2):135-142.
35. Kolstad A, Holte H, Fossa A, Lauritzsen GF, Gaustad P, Torfoss D. Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. Haematologica. 2007;92(1):139-140.
36. Sepkowitz KA. Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome: who should receive prophylaxis? Mayo Clin Proc. 1996;71(1):102-103.
37. El-Sadr WM, Luskin-Hawk R, Yurik TM, et al; Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). A randomized trial of daily and thrice-weekly trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected persons. Clin Infect Dis. 1999;29(4):775-783.
38. Imrie KR, Prince HM, Couture F, Brandwein JM, Keating A. Effect of antimicrobial prophylaxis on hematopoietic recovery following autologous bone marrow transplantation: ciprofloxacin versus co-trimoxazole. Bone Marrow Transplant. 1995;15(2):267-270.
39. Leoung GS, Stanford JF, Giordano MF, et al; American Foundation for AIDS Research (amfAR) Community-Based Clinical Trials Network. Trimethoprim- sulfamethoxazole (TMP-SMZ) dose escalation versus direct rechallenge for Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with previous adverse reaction to TMP-SMZ. J Infect Dis. 2001;184(8):992-997.
40. Dohn MN, Weinberg WG, Torres RA, et al; Atovaquone Study Group. Oral atovaquone compared with intravenous pentamidine for Pneumocystis carinii pneumonia in patients with AIDS. Ann Intern Med. 1994;121(3):174-180.
41. El-Sadr WM, Murphy RL, Yurik TM, et al; Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. N Engl J Med. 1998;339(26):1889-1895.
42. Teshale EH, Hanson DL, Wolfe MI, et al; Adult and Adolescent Spectrum of HIV Disease Study Group. Reasons for lack of appropriate receipt of primary Pneumocystis jiroveci pneumonia prophylaxis among HIVinfected persons receiving treatment in the United States: 1994-2003. Clin Infect Dis. 2007;44(6):879-883.
43. Kovacs JA, Hiemenz JW, Macher AM, et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med. 1984;100(5):663-671.
44. Gruden JF, Huang L, Turner J, et al. High-resolution CT in the evaluation of clinically suspected Pneumocystis carinii pneumonia in AIDS patients with normal, equivocal, or nonspecific radiographic findings. AJR Am J Roentgenol. 1997;169(4):967-975.
45. Ng VL, Yajko DM, Hadley WK. Extrapulmonary pneumocystosis. Clin Microbiol Rev. 1997;10(3):401-418.
46. Kovacs JA, Ng VL, Masur H, et al. Diagnosis of Pneumocystis carinii pneumonia: improved detection in sputum with use of monoclonal antibodies. N Engl J Med. 1988;318(10):589-593.
47. Larsen HH, Huang L, Kovacs JA, et al. A prospective, blinded study of quantitative touch-down polymerase chain reaction using oral-wash samples for diagnosis of Pneumocystis pneumonia in HIV-infected patients. J Infect Dis. 2004;189(9):1679-1683.
48. Bishop LR, Kovacs JA. Quantitation of anti-Pneumocystis jiroveci antibodies in healthy persons and immunocompromised patients. J Infect Dis. 2003;187(12):1844-1848.
49. Daly KR, Huang L, Morris A, et al. Antibody response to Pneumocystis jirovecii major surface glycoprotein. Emerg Infect Dis. 2006;12(8):1231-1237.
50. Skelly M, Hoffman J, Fabbri M, Holzman RS, Clarkson AB Jr, Merali S. S-adenosylmethionine concentrations in diagnosis of Pneumocystis carinii pneumonia. Lancet. 2003;361(9365):1267-1268.
51. Wang P, Huang L, Davis JL, et al. A hydrophilic-interaction chromatography tandem mass spectrometry method for quantitation of serum s-adenosylmethionine in patients infected with human immunodeficiency virus. Clin Chim Acta. 2008;396(1-2):86-88.
52. Kutty G, Hernandez-Novoa B, Czapiga M, Kovacs JA. Pneumocystis encodes a functional S-adenosylmethionine synthetase gene. Eukaryot Cell. 2008;7(2):258-267.
53. Tasaka S, Hasegawa N, Kobayashi S, et al. Serum indicators for the diagnosis of Pneumocystis pneumonia. Chest. 2007;131(4):1173-1180.
54. Shelhamer JH, Ognibene FP, Macher AM, et al. Persistence of Pneumocystis carinii in lung tissue of acquired immunodeficiency syndrome patients treated for pneumocystis pneumonia. Am Rev Respir Dis. 1984;130(6):1161-1165.
55. Hughes W, Leoung G, Kramer F, et al. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med. 1993;328(21):1521-1527.
56. Safrin S, Finkelstein DM, Feinberg J, et al. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS: a double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine: ACTG 108 Study Group. Ann Intern Med. 1996;124(9):792-802.
57. Sattler FR, Cowan R, Nielsen DM, Ruskin J. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a prospective, noncrossover study. Ann Intern Med. 1988;109(4):280-287.
58. Siegel SE, Wolff LJ, Baehner RL, Hammond D. Treatment of Pneumocystis carinii pneumonitis: a comparative trial of sulfamethoxazole-trimethoprim v pentamidine in pediatric patients with cancer: report from the Children's Cancer Study Group. Am J Dis Child. 1984;138(11):1051-1054.
59. Klein NC, Duncanson FP, Lenox TH, et al. Trimethoprim-sulfamethoxazole versus pentamidine for Pneumocystis carinii pneumonia in AIDS patients: results of a large prospective randomized treatment trial. AIDS. 1992;6(3):301-305.
60. Black JR, Feinberg J, Murphy RL, et al. Clindamycin and primaquine therapy for mild-to-moderate episodes of Pneumocystis carinii pneumonia in patients with AIDS: AIDS Clinical Trials Group 044. Clin Infect Dis. 1994;18(6):905-913.
61. The National Institutes of Health-University of California Expert Panel for Corticosteroids as Adjunctive Therapy for Pneumocystis Pneumonia. Consensus statement on the use of corticosteroids as adjunctive therapy for Pneumocystis pneumonia in the acquired immunodeficiency syndrome. N Engl J Med. 1990;323(21):1500-1504.
62. Bozzette SA, Sattler FR, Chiu J, et al; California Collaborative Treatment Group. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. N Engl J Med. 1990;323(21):1451-1457.
63. Kazanjian P, Locke AB, Hossler PA, et al. Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in AIDS patients. AIDS. 1998;12(8):873-878.
64. Crothers K, Beard CB, Turner J, et al. Severity and outcome of HIV-associated Pneumocystis pneumonia containing Pneumocystis jirovecii dihydropteroate synthase gene mutations. AIDS. 2005;19(8):801-805.
65. Helweg-Larsen J, Benfield TL, Eugen-Olsen J, Lundgren JD, Lundgren B. Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P carinii pneumonia. Lancet. 1999;354(9187):1347-1351.
66. Stein CR, Poole C, Kazanjian P, Meshnick SR. Sulfa use, dihydropteroate synthase mutations, and Pneumocystis jirovecii pneumonia. Emerg Infect Dis. 2004;10(10):1760-1765.
67. Walker DJ, Wakefield AE, Dohn MN, et al. Sequence polymorphisms in the Pneumocystis carinii cytochrome b gene and their association with atovaquone prophylaxis failure. J Infect Dis. 1998;178(6):1767-1775.